Q-omics provides the consensus-scored SLC25A18 profile across patient tissues and cancer cell-line models. SLC25A18 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC25A18 is differentially expressed in 10, with the highest sampling consensus in READ. Additionally, SLC25A18 RNA expression shows 16,798 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and READ as cancer lineages where SLC25A18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC25A18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC25A18 survival associations across molecular data types. SLC25A18 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC25A18 RNA expression–survival associations across cancer types. High SLC25A18 expression shows unfavorable associations in ACC and LUAD, but favorable associations in SKCM, UVM, KIRP and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC25A18 RNA expression.
This table summarizes SLC25A18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in READ for RNA.
This table ranks reproducible tumor–normal expression differences for SLC25A18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC25A18 shows lower tumor expression in READ, BRCA, CHOL, LIHC and LUSC and higher tumor expression in HNSC. The READ box plot shows higher SLC25A18 RNA expression in normal versus tumor tissue (log2 FC = −0.297, t-test p < 0.001).
This table shows molecular features associated with SLC25A18 in patient tissues and cancer cell lines. In patient samples, SLC25A18 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC25A18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
